Low-Dose Decitabine Priming Endows CAR T Cells with Enhanced and Persistent Antitumor Potential via Epigenetic Reprogramming

By
Justin.choi
-
0
20
Anti-tumor activities, cytokine production, and proliferation were enhanced in decitabine-treated chimeric antigen receptor T cells both in vitro and in vivo.
[Nature Communications]
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming | Nature Communications. (n.d.). Retrieved January 18, 2021, from https://www.nature.com/articles/s41467-020-20696-x Cite
Full Article